Aside from the mentioned studies, most preclinical and clinical research has centered on small-molecule PSMA inhibitors, mainly Lys-urea-Glu peptidomimetic scaffolds, due to their favorable pharmacokinetic and biodistribution profiles, efficient tumor penetration, high specificity, low immunogenicity, and ease of chemical synthesis and radiolabeling. The gene discussed is FOLH1; the disease is neoplasm.